Get started
Author

Nina S Budano

Observed name: Nina Budano
Observed institution: Dana-Farber Cancer Institute
OpenAlex ID: A5115006363
A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
2024 · Jorge J. Castillo, Shayna R Sarosiek, et al. · Blood · 9
PDF
A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia
2024 · Jorge J. Castillo, Steven P. Treon, et al. · Blood · 7
High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study
2025 · Jorge Castillo, Gottfried von Keudell, et al. · Blood · 5
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia
2025 · Jorge J. Castillo, Alberto Guijosa, et al. · Blood Advances · 5
Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.
2025 · Shayna Sarosiek, Mary Kwok, et al. · Blood · 3
PDF
Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications
2025 · Alberto Guijosa, Nickolas Tsakmaklis, et al. · Blood · 2
PDF
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
2026 · Jorge J. Castillo, Andrew R. Branagan, et al. · American Journal of Hematology · 1
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications
2026 · Alberto Guijosa, Nickolas Tsakamaklis, et al. · American Journal of Hematology · 1
Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia
2025 · Jorge Castillo, Andrew Branagan, et al. · Blood · 1
PDF
Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2024 · Jorge J. Castillo, Shayna R Sarosiek, et al. · Blood · 1
PDF
LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK
2025 · Maria Luisa Guerrera, Abigail Peachey, et al. · Blood
PDF
IBCL-884: Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia
2025 · Alberto Guijosa, Nicholas Tsakmaklis, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-884 Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia
2025 · Alberto Guijosa, Nicholas Tsakmaklis, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 13
Citation count: 35
H-index: 4
I10-index:
Year
Topic
Type